As of March 31, 2025, the Company had $220.6 million in cash, cash equivalents, and marketable securities, providing expected cash runway into 2027.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Is FHTX a Buy, Before Earnings?
- Foghorn Therapeutics Appoints New Board Members
- Foghorn Therapeutics appoints Neil Gallagher, Stuart Duty to board
- Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments
- Foghorn Therapeutics announces new preclinical data at AACR